Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014.

Cash and investments in marketable securities at June 30, 2014 were $301.4 million as compared to $309.1 million at March 31, 2014."The second half of 2014 will be an exciting time for Nektar as we look forward to significant milestones for a number of our late-stage clinical programs," said Howard W. Robin, President and Chief Executive Officer of Nektar. "The first of these is the potential US and EU approvals of Movantik™ with our partner AstraZeneca. If approved, Movantik would be the first oral targeted therapy approved for opioid induced constipation, a debilitating condition that occurs in up to 80%* of the 69 million chronic pain patients worldwide. Our partner Baxter has completed dosing in their Phase 3 study for BAX 855, a longer-acting PEGylated Factor VIII therapy to treat hemophilia A and plans to file the BLA in the U.S. by the end of this year. In our proprietary pipeline, we are on track for topline results from the Phase 3 breast cancer study for NKTR-102 in Q1 2015."

Revenue in the second quarter of 2014 was $28.5 million as compared to $33.9 million in the second quarter of 2013. Year-to-date revenue for 2014 was $48.3 million as compared to $56.9 million in the first half of 2013.  The decrease in revenue in the second quarter and first half of 2014 as compared to the same periods in 2013 is primarily due to decreased manufacturing activity.  Revenue included non-cash royalty revenue, related to our 2012 royalty monetization, of $4.8 million and $10.6 million in the second quarter and first half of 2014, respectively, and $3.8 million and $8.2 million in the second quarter and first half of 2013, respectively. This non-cash royalty revenue is offset by non-cash interest exp
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... for the fourth quarter and year ended December 31, ... or less than $0.01 per share, on revenues of ... compares with net income of $195,000, or $0.01 per ... of 2013. The substantial increase in fourth quarter 2014 ...
(Date:3/6/2015)... March 6, 2015  AbbVie (NYSE: ABBV ... Conference on Thursday, March 12, 2015. Richard A. ... in a question and answer session at 8:30 a.m. ... the presentation will be accessible through AbbVie,s Investor Relations ... of the session will be available later that day. ...
(Date:3/6/2015)... de 2015 TeraRecon, ( www.terarecon.com ), ... imagen médica, fortalece su posición dentro del mercado ... Sternberg como director de ventas y de ... Logo - http://photos.prnewswire.com/prnh/20150303/179359LOGO ... las ventas y desarrollo empresarial en Europa, proporcionando ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 2Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 4Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 5TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3
... the Potential Utility of Modigene,s CTP Technology ... ... Va., Sept. 24 Modigene Inc. (OTC,Bulletin Board: MODG) today reported ... journal Endocrinology showing that,erythropoietin (EPO) linked to Modigene,s carboxyl terminal peptide ...
... 24 Iodine has been used as an,antimicrobial ... about molecular,iodine yet many women suffering from Fibrocystic ... may soon yield an effective,nonhormonal treatment. While ... market, all,available hormonal therapies have significant adverse events. ...
Cached Medicine Technology:Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 2Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 3Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 4Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease 2
(Date:3/6/2015)... 2015 Johnson & Johnson and Ethicon ... March 5, 2015 in Superior Court in the State ... a jury of 12 awarded Mrs. Perry $700,000 in ... with an Ethicon TVT Abbrevo plastic sling for stress ... women also awarded $5 million in punitive damages. , ...
(Date:3/6/2015)... Magellan Rx Management’s 2014 Medical Pharmacy Trend Report ... and statistics on one of the nation’s biggest drivers ... Management will discuss key findings from the report in ... Spend,” a complimentary March 19 webinar, managed and moderated ... makes up more than a quarter of total drug ...
(Date:3/6/2015)... 06, 2015 The Gluten-Free Certification ... Association, is pleased to announce that Dufflet Pastries, ... has expanded their product line of gluten-free treats ... scrumptious and as satisfying as any of their ... and never contains hydrogenated fats or oils, artificial ...
(Date:3/6/2015)... 2015 Dr. Mark Sowell recently returned from ... AZ. Offering programs for advanced education in the field of ... , As a visiting faculty member of this prestigious ... each time he visits Spear Education to participate in a ... “we are training only the top 10% and those willing ...
(Date:3/5/2015)... 2015 From Oct. 5-10, Mumbai, India will ... Conference . These dates include the following activities:, ... , October 6: Conference Day 1, ending with ... Conference Day 2, ending with Local Entertainment and Dinner , ... and other Materials Meetings , October 9-10: Textiles ...
Breaking Medicine News(10 mins):Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4Health News:Plano Dentist Teaches Dentists from Around the Globe at Spear Education 2Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2
... As part of a Research and Development partnership ... joins Halo Pharmaceutical as Chief Scientific Officer. Halo and ... the development of several client products. "I am excited ... and the opportunity to work closely together with a ...
... Care Accessible to EveryoneCARLSBAD, Calif., April 20 Today,s woman ... kids, managing a career and household, and may even be ... deserves a break and, even in these tough times, she ... image possible."In a time like this, it,s more important than ...
... Health Survey Shows Physician Visits Are First to Go When ... are postponing healthcare due to cost, according to a study ... A total of 20 percent of U.S. households postponed or ... 2006. Among those who postponed or cancelled care, 24.1 ...
... website that lets cash-paying patients shop and compare prices ... With an estimated 700,000 people without health ... insurance, finding affordable healthcare can ... have health insurance find that vision, dentistry, cosmetic, or ...
... St. Louis, April 20, 2009 The search for ... aggressive childhood lung cancer has uncovered important information about ... the development of other cancers. , The finding ... St. Louis, Children,s National Medical Center in Washington, D.C., ...
... the edge off, manage intakeNEW ORLEANS, April 20 ... Redenbacher,s 94 percent fat-free SmartPop! popcorn, before a meal ... calorie intake, says a new study released today.Guided by ... Rippe Lifestyle Institute, the study found that subjects who ...
Cached Medicine News:Health News:Halo Pharmaceutical Welcomes Dr. George Bobotas as Its Chief Scientific Officer 2Health News:She Works Hard for the Money, so She Shouldn't Have to Work Hard for Great Skin 2Health News:She Works Hard for the Money, so She Shouldn't Have to Work Hard for Great Skin 3Health News:Thomson Reuters Study Finds More Patients Postponing Medical Care Due to Cost 2Health News:Thomson Reuters Study Finds More Patients Postponing Medical Care Due to Cost 3Health News:New Website Helps Families Find Better Healthcare at a Better Price 2Health News:Genetic source of rare childhood cancer found; gene is implicated in other cancers 2Health News:Genetic source of rare childhood cancer found; gene is implicated in other cancers 3Health News:Squeezing Calories? New Study Finds That Low-Fat Popcorn Before Lunch Does Not Increase Total Calorie Intake 2
Round serrated handle, polished finish, overall length 130 mm....
... Menicon Super EX is a rigid ... one of its specific characteristics as hard ... correction and show excellent performance against astigmatism. ... material is the combination of fluoromethacrylate, Siloxanylmethacrylate ...
Achievement, available exclusively from Art Optical, is a unique RGP lens design with a patented junctionless back surface and a controlled edge lift....
... Gp is a simultaneous vision ... surface. Through a series of ... the LifeStyle Gp delivers up ... Plus, its multi-aspheric center-distance design ...
Medicine Products: